ReviewWorld journal of clinical oncology2025
Regulation of matrix metalloproteinase-13 in cancer: Signaling pathways and non-coding RNAs in tumor progression and therapeutic targeting.
Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Cumulative evidence for associations between matrix metalloproteinase-1, -3 and -8 variants and cancer risk.Oncology letters · 2026Article
- Therapeutic Potential of Allomyrinasin in Oral Squamous Cell Carcinoma via Decreased NBC Activity.Pharmaceutics · 2026Article
- Advances in Extracellular Matrix Metalloproteinases: Implications for Renal Cell Carcinoma Pathophysiology, Diagnostics, and Therapeutics.Medicines (Basel, Switzerland) · 2026Review
- Therapeutic potential of TAS-115 in 3D breast cancer models.Biofabrication · 2025Article
- Recent advances in the investigation of the regulatory network underlying reactive nitrogen species-mediated tumorigenesis: molecular mechanisms and targeted therapeutic strategies.Redox report : communications in free radical research · 2025Review
- Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinases (MMPs) are essential enzymes involved in extracellular matrix degradation and remodeling. Such processes are integral to normal tissue homeostasis and several pathological conditions such as cancer. Among these MMPs, MMP-13 plays a key role in cancer progression, driving tumor invasion, metastasis, and angiogenesis. Despite significant advancements in understanding its biology, therapeutic targeting of MMP-13 remains challenging owing to its complex and multifaceted regulatory mechanisms. Recent studies have underscored the pivotal role of non-coding RNAs (ncRNAs), including long ncRNAs, microRNAs, and circular RNAs, in modulating MMP-13 expression. This review provides a comprehensive analysis of MMP-13 regulation by several signaling pathways, the influence of ncRNAs on these signaling pathways, and MMP-13 expression during cancer progression and metastasis. Furthermore, we explored the clinical relevance of ncRNA-mediated regulatory networks, highlighting their potential as diagnostic biomarkers and therapeutic targets in various cancers. By unraveling these regulatory mechanisms, this review offers valuable insights into innovative strategies for cancer diagnosis and treatment and emphasizes the translational significance of ncRNA-mediated MMP-13 regulation in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.